Company name: Therapix Biosciences (Non-Pain Assets)
Description: Non-pain assets of Therapix Biosciences. These assets include several clinical drug candidates as well as two pre-clinical drug candidates.
Industry: Business Products and Services (B2B) | Group: Other Business Products and Services | Code:
Region: Middle East
Start up capital raised (USD Million):
Ownership: Publicly Held
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: CURE Pharmaceutical (OTCQB: CURR) entered into a definitive agreement to acquire Therapix Biosciences (Non-Pain Assets) from Therapix Biosciences (Nasdaq: TRPX) for an undisclosed amount on July 11, 2018. The acquisition will combine Therapix’s promising clinical programs with CURE’s proprietary drug delivery technology and manufacturing capabilities and is a further step in CURE’s efforts toward up-listing to the NASDAQ.
Number of active investors:
Profile last updated: 08-Sep-2018
Last known valuation:
Last known valuation date: